Literature DB >> 1618852

Purification of nuclear proteins that bind to cisplatin-damaged DNA. Identity with high mobility group proteins 1 and 2.

E N Hughes1, B N Engelsberg, P C Billings.   

Abstract

The biochemical processes responsible for the recognition and repair of cisplatin-damaged DNA in human cells are not well understood. We have developed a damaged DNA affinity precipitation technique that allows the direct visualization and characterization of cellular proteins that bind to cisplatin-damaged DNA. The method separates damaged DNA-binding proteins from complex radiolabeled cell mixtures and further resolves them into individual polypeptides by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. This technique is complementary to gel retardation and Southwestern blotting analyses that have been previously used to identify cellular components that specifically bind to cisplatin-damaged DNA. Using this technique, we have characterized a set of HeLaS3 nuclear proteins of 26.5, 28, 90, and 97 kDa that specifically bind to cisplatin-DNA adducts. Competition studies with soluble cisplatin-damaged DNA confirmed these findings. The major cisplatin-damaged DNA-binding proteins of 26.5 and 28 kDa recognized adducts of DNA modified with cisplatin but not with its trans-isomer or with UV radiation. These proteins were purified 450-fold to near homogeneity by ion-exchange and cisplatin-damaged DNA affinity chromatography. Amino-terminal sequence analysis showed that the 26.5- and 28-kDa proteins were identical to high mobility group (HMG) proteins HMG-2 and HMG-1, respectively.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1618852

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  35 in total

1.  Interaction of nuclear proteins with intrinsically curved DNA in a matrix attachment region of a tobacco gene.

Authors:  Y Fukuda
Journal:  Plant Mol Biol       Date:  2000-09       Impact factor: 4.076

2.  Transcription-coupled and DNA damage-dependent ubiquitination of RNA polymerase II in vitro.

Authors:  Keng-Boon Lee; Dong Wang; Stephen J Lippard; Phillip A Sharp
Journal:  Proc Natl Acad Sci U S A       Date:  2002-03-19       Impact factor: 11.205

3.  Human MutSalpha recognizes damaged DNA base pairs containing O6-methylguanine, O4-methylthymine, or the cisplatin-d(GpG) adduct.

Authors:  D R Duckett; J T Drummond; A I Murchie; J T Reardon; A Sancar; D M Lilley; P Modrich
Journal:  Proc Natl Acad Sci U S A       Date:  1996-06-25       Impact factor: 11.205

Review 4.  The role of chromatin proteins in DNA damage recognition and repair.

Authors:  Piotr Widlak; Monika Pietrowska; Joanna Lanuszewska
Journal:  Histochem Cell Biol       Date:  2006-01       Impact factor: 4.304

5.  Photoaffinity isolation and identification of proteins in cancer cell extracts that bind to platinum-modified DNA.

Authors:  Evan R Guggenheim; Dong Xu; Christiana X Zhang; Pamela V Chang; Stephen J Lippard
Journal:  Chembiochem       Date:  2009-01-05       Impact factor: 3.164

Review 6.  High mobility group proteins and their post-translational modifications.

Authors:  Qingchun Zhang; Yinsheng Wang
Journal:  Biochim Biophys Acta       Date:  2008-05-10

7.  Recognition of DNA alterations by the mismatch repair system.

Authors:  G Marra; P Schär
Journal:  Biochem J       Date:  1999-02-15       Impact factor: 3.857

8.  Human HMGB1 directly facilitates interactions between nucleotide excision repair proteins on triplex-directed psoralen interstrand crosslinks.

Authors:  Sabine S Lange; Madhava C Reddy; Karen M Vasquez
Journal:  DNA Repair (Amst)       Date:  2009-05-14

9.  Binding interaction of HMGB4 with cisplatin-modified DNA.

Authors:  Semi Park; Stephen J Lippard
Journal:  Biochemistry       Date:  2012-08-17       Impact factor: 3.162

10.  Cisplatin-DNA adducts are molecular decoys for the ribosomal RNA transcription factor hUBF (human upstream binding factor).

Authors:  D K Treiber; X Zhai; H M Jantzen; J M Essigmann
Journal:  Proc Natl Acad Sci U S A       Date:  1994-06-07       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.